Halozyme Therapeutics HALO Enterprise value
Enterprise value at other companies
Other financials
Where this comes from
Calculated from Halozyme Therapeutics’s reported figures.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's enterprise value.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's enterprise value?
- Halozyme Therapeutics (HALO) reported enterprise value of $9.52B in Q1 2026.
- How has Halozyme Therapeutics's enterprise value changed year-over-year?
- Halozyme Therapeutics's enterprise value increased by 3.0% year-over-year, from $9.24B to $9.52B.
- What is the long-term trend for Halozyme Therapeutics's enterprise value?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's enterprise value has grown at a 10.1% compound annual growth rate (CAGR), from $6.15B to $9.96B.
- What does enterprise value mean?
- What it would cost to buy the entire business, debt included and cash netted out.
- How do you interpret enterprise value?
- The capital-structure-neutral valuation base — used in EV/EBITDA and EV/Sales to compare companies with different leverage on a like-for-like footing.
- How does enterprise value compare across companies?
- Comparable across non-financial companies via the EV multiples it feeds; not used for banks and insurers.